The VWM Consortium paper is Neurology Genetics' #2 most read paper of 2022!

In an end-of-the-year countdown on Facebook, the scientific journal ‘Neurology: Genetics’ stated that their #2 most read paper of 2022 is the VWM Consortium paper on therapy trial design.

The VWM Consortium is thankful that this paper has reached so many readers, and will continue their best efforts in 2023 to work towards optimal trial design for VWM patients. Happy 2023!

More News Articles

All News

21 augustus 2023

The core protocol for phase 2/3 clinical trial(s) in VWM is now published

The core protocol for phase 2/3 clinical trial(s) in VWM, aimed to serve as a template for industry-sponsored clinical trials in VWM, is now published.

26 april 2023

Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease

26 maart 2023

Calico starts phase 1b study evaluating safety, tolerability and pharmacokinetics of eIF2B activator

Calico starts phase 1b study evaluating safety, tolerability and pharmacokinetics of eIF2B activator.

The VWM Consortium paper is Neurology Genetics’ #2 most read paper of 2022!